Health related quality of life in patients with chronic gastritis and peptic ulcer and factors with impact: a longitudinal study

BMC Gastroenterology

Pingguang Lei²  Chonghua Wan³  Jianfeng Tan³  Miao Zhao²  Julie Brunson¹  Qian Lu⁵  Xiaomei Li⁴  Zhengwei Wen² 

[1] Department of Psychology, Pennsylvania State University, Pennsylvania, PA, USA;People’s Hospital of Songgang, Baoan, Shenzhen, Guangdong 518105, China;School of Humanities and Management, Research Center for Quality of Life and Applied Psychology, Guangdong Medical College, Dongguan 523808, China;School of Public Health, Kunming Medical University, Kunming, Yunnan 650031, China;Department of Psychology, University of Houston, Houston, TX 77204, USA

关键词: Standardized response mean;    Influence factors;    SF-36;    Health-related quality of life;    Chronic digestive disease;   

Others  :  1121835
DOI  :  10.1186/1471-230X-14-149

 received in 2013-03-31, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background

The assessment of Health Related Quality of Life (HRQOL) has been applied as a significant outcome indicator for patients with chronic diseases. No HRQOL study, however, has looked at HRQOL in patients with chronic gastritis and peptic ulcers. This paper focuses on comparing HRQOL in patients with chronic gastritis and peptic ulcers and examining the factors that influence the HRQOL of such patients. Results can be used for making decisions in clinical trials as well as aiding individual management and preventive care of these diseases.

Methods

The Chinese version of the SF-36 (CSF-36) was administered twice to 244 patients with chronic gastritis and peptic ulcers. Mean scores across the two disease groups were compared using t-tests, change over time was analyzed with paired samples t-tests, and factors predicting HRQOL were investigated using the univariate general linear model.

Results

The mean domain scores of patients with chronic gastritis were lower than those for patients with peptic ulcers, with the exception of physical functioning. Both groups had lower HRQOL compared with population norms. Mean domain scores increased after treatment in both groups. HRQOL in patients with these two chronic diseases differed by age, education level, marriage, income, and gender, but their explanatory power was relatively low.

Conclusion

Quality of life of patients with chronic gastritis was lower than that of patients with peptic ulcers, which was lower than population norms. Quality of life in both patients groups was associated with socio-demographic risk factors.

【 授权许可】

   
2014 Wen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sonnenberg A, Everhart JE: Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997, 92:614-620.
• [2]Borgaonkar MR, Irvine EJ: Quality of life measurement in gastrointestinal and liver disorders. Gut 2000, 47(3):444-454.
• [3]Choi MG, Jung HK: Health related quality of life in functional gastrointestinal disorders in Asia. J Neurogastroenterol Motil 2011, 17(3):245-251.
• [4]Stewart AL, Hays RD, Ware JE Jr, The MOS: Short-form general health survey. Reliability and validity in a patient population. Med Care 1988, 26:724-735.
• [5]Ware JE Jr: SF-36 health survey update. Spine 2000, 25(24):3130-3139.
• [6]Li L, Wang HM, Shen Y: Chinese SF-36 health survey: translation, cultural adaptation, validation and normalization. J Epidemiol Community Health 2003, 57:259-263.
• [7]Yang Z, Li W, Tu X, Tang W, Messing S, Duan LP, Pan JH, Li XM, Wan CH: Validation and psychometric properties of Chinese version of SF-36 in patients with hypertension, coronary heart diseases, chronic gastritis and peptic ulcer. Int J Clin Pract 2012, 66(10):991-998.
• [8]Mokrowiecka A, Jurek K, Pińkowski D, Małecka-Panas E: The comparison of health-related quality of life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. Adv Med Sci 2006, 51:142-147.
• [9]Gonzàlez-Stawinski GV, Rovak JM, Seigler HF, Grant JP, Kalady MF, Biswas S, Pappas TN: Poor outcome and quality of life in female patients undergoing secondary surgery for recurrent peptic ulcer disease. J Gastrointest Surg 2002, 6(3):396-402.
• [10]Ruta DA, Garratt AM, Russell IT: Patient centred assessment of quality of life for patients with four common conditions. Qual Health Care 1999, 8(1):22-29.
• [11]Hallerbäck B: Assessment of Quality of Life among patients with suspected duodenal ulcer. Scand J Gastroenterol Suppl 1993, 199:32-33.
• [12]Ware JE, Snow KK, Kosinski M: SF36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
• [13]Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PM: On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res 2003, 12(4):349-363.
• [14]Husted JA, Cook RJ, Farewell VT, Gladman DD: Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000, 53(5):459-468.
• [15]Lin J, Zhang LJ, Zheng SH, Cai G: Relationship between quality of life factors s and Chinese medical syndromes in patients with chronic gastritis. Shanghai J Tradition Chinese Med 2006, 40(8):4-5.
• [16]Mant JWF, Jenkinson C, Murphy MFG, Clipsham K, Marshall PO, Vessey MP: Use of the Short Form-36 to detect the influence of upper gastrointestinal disease on self-reported health status. Qual Life Res 1998, 7:221-226.
• [17]Cutts TF, Abell TL, Karas JG, Kuns J: Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996, 41:1369-1378.
• [18]Moyer CA, Fendrick AM: Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998, 16:315-324.
• [19]Wiklund I, Butler-Wheelhouse P: Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol 1996, 31(Suppl 220):94-100.
• [20]Glise H: Quality of Life assessments in patients with peptic ulcer during treatment and follow-up. Scand J Gastroenterol Suppl 1993, 199:34-55.
• [21]Glise H, Hallerback B, Johansson B: Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterl 1995, 30(Suppl 208):133-135.
• [22]Wan CH, Tu XM, Messing S, Li XM, Yang Z, Zhao XD, Gao L, Yang YP, Pan JH, Zhou ZF: Development and validation of the general module (QLICD-GM) of the system of quality of life instruments for chronic diseases and comparison with SF-36. J Pain Symptom Manage 2011, 42(1):93-104.
• [23]Wensing M, Vingerhoets E, Grol R: Functional status, health problems, age and comorbidity in primary care patients. Qual Life Res 2001, 10:141-148.
• [24]Woolf SH, Rothemich SF, Johnson RE: The functional status of inner-city primary care patients. Diminished function in a family practice population and its potential determinants. J Fam Pract 1998, 47:312-315.
• [25]Sullivan M, Karlsson J: The Swedish SF-36 health survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol 1998, 51:1105-1113.
• [26]Loge JH, Kaasa S: Short-form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998, 26:250-258.
• [27]Jenkinson C, Layte R, Coulter A, Wright L: Evidence for the sensitivity of the SF-36 health status measure to inequalities in health: results from the Oxford healthy lifestyles survey. J Epidemiol Community Health 1996, 50:377-380.
• [28]Jörngården A, Wettergen L, von Essen L: Measuring health-related quality of life in adolescents and young adults: Swedish normative data for the SF-36 and the HADS, and the influence of age, gender, and method of administration. Health Qual Life Outcomes 2006, 4:91. BioMed Central Full Text
• [29]Raty LK, Wilde Larsson BM, Soderfeldt BA: Health-related quality of life in youth: a comparison between adolescents and young adults with uncomplicated epilepsy and healthy controls. J Adolesc Health 2003, 33(4):252-258.
• [30]Eiser C: Use of quality of life measures in clinical trials. Ambul Pediatr 2004, 4(4 Suppl):395-399.
• [31]Marquis P, Caron M, Emery MP: The Role of health-related quality of life data in the drug approval processes in the US and Europe: A review of guidance documents and authorizations of medicinal products from 2006 to 2010. Pharm Med 2011, 25(3):147-160.